The interplay between DNA and histone methylation: molecular mechanisms and disease implications

Y Li, X Chen, C Lu - EMBO reports, 2021 - embopress.org
Methylation of cytosine in CpG dinucleotides and histone lysine and arginine residues is a
chromatin modification that critically contributes to the regulation of genome integrity …

Merging ligand-based and structure-based methods in drug discovery: an overview of combined virtual screening approaches

J Vázquez, M López, E Gibert, E Herrero, FJ Luque - Molecules, 2020 - mdpi.com
Virtual screening (VS) is an outstanding cornerstone in the drug discovery pipeline. A variety
of computational approaches, which are generally classified as ligand-based (LB) and …

Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease

KP Bhat, H Ümit Kaniskan, J **… - Nature Reviews Drug …, 2021 - nature.com
Protein lysine methylation is a crucial post-translational modification that regulates the
functions of both histone and non-histone proteins. Deregulation of the enzymes or 'writers' …

A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization

D Dilworth, RP Hanley, R Ferreira de Freitas… - Nature chemical …, 2022 - nature.com
Nuclear receptor-binding SET domain-containing 2 (NSD2) is the primary enzyme
responsible for the dimethylation of lysine 36 of histone 3 (H3K36), a mark associated with …

Drug discovery targeting nuclear receptor binding SET domain protein 2 (NSD2)

Z Ma, AA Bolinger, H Chen, J Zhou - Journal of medicinal …, 2023 - ACS Publications
Nuclear receptor binding SET domain proteins (NSDs) catalyze the mono-or dimethylation
of histone 3 lysine 36 (H3K36me1 and H3K36me2), using S-adenosyl-l-methionine (SAM) …

The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors

I Topchu, RP Pangeni, I Bychkov, SA Miller… - Cellular and Molecular …, 2022 - Springer
Abstract NSD1, NSD2, and NSD3 constitute the nuclear receptor-binding SET Domain
(NSD) family of histone 3 lysine 36 (H3K36) methyltransferases. These structurally similar …

Discovery of a first-in-class degrader for nuclear receptor binding SET domain protein 2 (NSD2) and Ikaros/Aiolos

F Meng, C Xu, KS Park, HU Kaniskan… - Journal of medicinal …, 2022 - ACS Publications
Overexpression of nuclear receptor binding SET domain protein 2 (NSD2) is frequent in
multiple myeloma (MM). However, existing NSD2 inhibitors are largely ineffective in …

Identification of novel potent NSD2-PWWP1 ligands using structure-based design and computational approaches

L Carlino, PC Astles, B Ackroyd, A Ahmed… - Journal of Medicinal …, 2024 - ACS Publications
Dysregulation of histone methyl transferase nuclear receptor-binding SET domain 2 (NSD2)
has been implicated in several hematological and solid malignancies. NSD2 is a large …

Evaluating the use of absolute binding free energy in the fragment optimisation process

I Alibay, A Magarkar, D Seeliger… - Communications Chemistry, 2022 - nature.com
Key to the fragment optimisation process within drug design is the need to accurately
capture the changes in affinity that are associated with a given set of chemical modifications …

Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives

L Zhang, X Zha - European Journal of Medicinal Chemistry, 2023 - Elsevier
Nuclear receptor-binding SET domain 2 (NSD2) is a histone lysine methyltransferase
(HKMTase), which is mainly responsible for the di-methylation of lysine residues on …